Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading
UPDATE: On July 13, 2018, KEI received a response to our comments on the prospective license to be given to ERYTHRYx Therapeutics. The brief response simply stated that NIH had already assessed the company to meet their technical and financial… Continue Reading
On June 28, 2018, the U.S. Senate provided the necessary advice and consent for ratification of the WIPO Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired or Otherwise Print Disabled. At present, 39… Continue Reading
The NIH has filed a motion to dismiss in our lawsuit over the NIH license of CAR T patents to Gilead. See original KEI complaint here: https://www.keionline.org/27669. As expected, the NIH is challenging KEI’s standing. KEI has 15 days to… Continue Reading
(Update: The NIH provided a response to our comments on July 16, 2018) Below are comments sent by KEI, UACT and HealthGap, regarding a proposed exclusive license to Morphiex Biotherapeutics, an entity for which little is known. The license concerns… Continue Reading
The revised Chair’s text (SCCR/36/6) is very responsive to the broadcasters, and mostly hostile to the civil society groups’ positions, on issues such as term and exceptions, and extending the right to materials delivered over the Internet. One bright spot… Continue Reading
I’m about to deliver this intervention at the WIPO SCCR 36 meeting, as a general statement on limitations and exceptions. We are given 2 minutes. KEI has three points 1. The 1971 Berne Annex, which deals with access for developing… Continue Reading
On May 28, 2018, at the opening of a five day to talks at the 36th WIPO Standing Committee on Copyright and Related Rights (SCCR), 11 civil society and library groups sent a letter to negotiators expressing deep concerns over… Continue Reading
The below are comments were filed by KEI and HealthGap on May 22, 2018, regarding a proposed NIH exclusive license on patents for the treatment and diagnosis of Crohn’s Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis to Precision IBD… Continue Reading
On Wed, May 16, 2018, the House Ways & Means Committee held a markup on HR. 5773, a bill dealing with the opioid crisis, which would require Medicare prescription drug plans to establish drug management programs for at-risk beneficiaries. Representative… Continue Reading